Janus Henderson Group PLC grew its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 11.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 150,886 shares of the medical equipment provider’s stock after purchasing an additional 15,582 shares during the quarter. Janus Henderson Group PLC owned approximately 0.07% of Zimmer Biomet worth $17,666,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Bronfman E.L. Rothschild L.P. boosted its position in Zimmer Biomet by 25.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after acquiring an additional 167 shares during the last quarter. FNY Managed Accounts LLC acquired a new position in Zimmer Biomet during the third quarter worth about $117,000. BB&T Investment Services Inc. acquired a new position in Zimmer Biomet during the second quarter worth about $144,000. Sandy Spring Bank boosted its position in Zimmer Biomet by 5.4% during the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock worth $166,000 after acquiring an additional 66 shares during the last quarter. Finally, Penserra Capital Management LLC boosted its position in Zimmer Biomet by 13.0% during the second quarter. Penserra Capital Management LLC now owns 1,456 shares of the medical equipment provider’s stock worth $186,000 after acquiring an additional 168 shares during the last quarter. Institutional investors and hedge funds own 85.92% of the company’s stock.
ZBH has been the topic of a number of recent research reports. Deutsche Bank upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price target on the stock in a research report on Tuesday, November 14th. Zacks Investment Research lowered shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, November 20th. Edward Jones upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Thursday, November 9th. TheStreet lowered shares of Zimmer Biomet from a “b-” rating to a “c+” rating in a research report on Friday, November 24th. Finally, SunTrust Banks set a $136.00 price target on shares of Zimmer Biomet and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $136.90.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. Zimmer Biomet’s revenue was down .8% on a year-over-year basis. During the same period last year, the firm posted $1.79 earnings per share. sell-side analysts anticipate that Zimmer Biomet Holdings Inc will post 8.03 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Stockholders of record on Friday, December 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s dividend payout ratio (DPR) is 29.91%.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/12/24/zimmer-biomet-holdings-inc-zbh-shares-bought-by-janus-henderson-group-plc.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.